How it works
Selectively activates MC4R in the hypothalamus, increasing dopaminergic signalling in the medial preoptic area — driving desire itself rather than blood flow, unlike PDE5 inhibitors.
Structure: Cyclic heptapeptide, Melanotan II metabolite
Reported benefits
- Increased sexual desire in both sexes
- Works independently of vascular function
- Effective as an on-demand dose
Practical considerations
- Raises blood pressure transiently — avoid with uncontrolled hypertension
- Nausea is common at higher doses
- Label limits use to eight doses per month
Side effects and risks
- Nausea and vomiting
- Flushing
- Headache
- Transient blood-pressure increase
Dosing overview
1.75 mg as needed, maximum one dose per 24 hours
This describes doses reported in published literature and community protocols. It is not a recommendation, and it is not a substitute for clinical supervision.
Research references
- Kingsberg et al., 2019 — RECONNECT trials of bremelanotide